No results for ‘’
Beryl Drugs Ltd
₹20.10
(0%)
Sat, 30 May 2026, 07:05 am
Health Technology
Pharmaceuticals: Other
24.5KBeryl Drugs Debt to Equity Ratio
| Particulars | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price to earnings ratio | 317 | 185 | 118.44 | 100 | 36.97 | 69.53 | 218.53 | 98.03 | 63.04 | 6.12 | 7.18 | 38.62 | 13.99 | 0 | 8.05 | 19.35 | 18.45 |
| Price to book ratio | 0.87 | 0.84 | 1.70 | 1.51 | 2.34 | 2.93 | 2.92 | 2.48 | 1.25 | 0.91 | 0.56 | 0.24 | 0.42 | 0.73 | 0.76 | 1.67 | 1.12 |
| Price to sales ratio | 0.69 | 0.69 | 1.31 | 0.95 | 1 | 1.29 | 1.42 | 1.26 | 0.67 | 0.40 | 0.33 | 0.14 | 0.24 | 0.37 | 0.23 | 0.56 | 0.51 |
| Price to cash flow ratio | 22.14 | 15.92 | 126.60 | 14.28 | 22.50 | 0 | 71.31 | 0 | 25.55 | 0 | 1.21 | 0 | 0 | 0 | 3.15 | 41.70 | 5.07 |
| Enterprise value | 56.16M | 54.25M | 106.81M | 94.57M | 144.99M | 199.82M | 197.45M | 174.74M | 84.33M | 74.23M | 73.85M | 66.9M | 78.22M | 99.22M | 101.35M | 197.46M | 138.68M |
| Enterprise value to EBITDA ratio | 12.29 | 10.61 | 29.93 | 19.88 | 15.63 | 25.97 | 26.78 | 33.91 | 17.02 | 7.02 | 7.22 | 7.39 | 5.39 | 23.83 | 5.16 | 8.65 | 11.25 |
| Debt to equity ratio | 0.17 | 0.14 | 0.18 | 0.16 | 0.15 | 0.24 | 0.27 | 0.26 | 0.29 | 0.22 | 0.43 | 0.69 | 0.65 | 0.73 | 0.56 | 0.57 | 0.43 |
| Return on equity % | 0 | 0.43 | 1.47 | 1.56 | 6.64 | 4.29 | 1.32 | 2.55 | -7.16 | 14.80 | 8.32 | 0.63 | 3.08 | -8.66 | 9.97 | 9.05 | 6.28 |
Beryl Drugs Ltd Debt to Equity Ratio
The Beryl Drugs Ltd Debt to Equity Ratio is a key financial metric used by investors to evaluate Beryl Drugs Ltd's valuation, profitability, and overall financial performance. Tracking the Beryl Drugs Ltd Debt to Equity Ratio helps investors understand whether the stock is undervalued, fairly valued, or trading at a premium compared to its historical performance and industry peers.
Beryl Drugs Ltd (NSE: , BSE: 524606) is currently trading at ₹20.10, with a market capitalization of ₹101.94M. As a leading company in the Health technology sector and Pharmaceuticals: other industry, monitoring the Beryl Drugs Ltd Debt to Equity Ratio is essential for fundamental analysis.
Beryl Drugs Ltd Debt to Equity Ratio Current Value
The current Beryl Drugs Ltd Debt to Equity Ratio stands at 0.43.
The Beryl Drugs Ltd Debt to Equity Ratio has declined compared to earlier levels, suggesting improved fundamentals or more attractive valuation.
Beryl Drugs Ltd Debt to Equity Ratio Historical Trend
The Beryl Drugs Ltd Debt to Equity Ratio has shown the following historical trend:
- 2024: 0.43
- 2023: 0.57
- 2022: 0.56
- 2021: 0.73
- 2020: 0.65
The decline in Beryl Drugs Ltd Debt to Equity Ratio indicates improving financial efficiency or better earnings growth.
What Beryl Drugs Ltd Debt to Equity Ratio Indicates for Investors
The Beryl Drugs Ltd Debt to Equity Ratio plays a crucial role in understanding the company's financial health and valuation.
The D/E ratio measures financial leverage and balance sheet strength.
Beryl Drugs Ltd Debt to Equity Ratio Analysis Summary
The Beryl Drugs Ltd Debt to Equity Ratio remains a crucial metric for evaluating the company's valuation and financial stability. Investors tracking Beryl Drugs Ltd Debt to Equity Ratio should also monitor related metrics such as P/E, P/B, EV/EBITDA, D/E, and ROE to get a complete fundamental picture.
Regular tracking of Beryl Drugs Ltd Debt to Equity Ratio helps investors make informed decisions based on long-term growth, valuation trends, and financial performance.